3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
10
Thoracic
2
Breast
2
Genitourinary
1
Dermatologic
1
Conditions
Melanoma
2
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
cemiplimab
3
Cyclophosphamide
3
temsirolimus
2
palbociclib
2
cediranib
2
Therapeutics
2
Radiotherapy
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Methods
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Gemcitabine
2
Fluorouracil
2
Drug Therapy
2
Docetaxel
2
Cisplatin
2
Capecitabine
2
Biological Therapy
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tanespimycin
1
sonidegib
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Propofol
×
Dermatologic
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled